Annual report
4539.TEDINET S100OBPY
Period2021-04-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥31.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥31.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥34.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥35.3bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥825m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥564m | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥582m | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥307m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥976m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥713m | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥700m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥495m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥436m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥881m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥700m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥495m | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥49.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥47.1bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥45.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥46.9bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥46.7bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥31.0bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥29.1bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.0bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥17.4bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥17.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥17.5bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.9bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥35m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.0bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥326m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥960m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥793m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥29m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥961m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥110m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥194.33 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.75 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.42 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥245.11 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥315.28 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,119.99 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,006.49 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,830.92 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,963.24 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,859.86 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 37.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.2% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 809 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 760 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 807 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 846 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 816 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥24.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥24.4bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥25.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥29.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥355m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥286m | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | −¥2m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥690m | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥309m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥574m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥769m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥113m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥822m | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥249m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥643m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥86m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥479m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥748m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥35.1bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥34.6bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥32.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥34.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥34.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥24.1bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥23.5bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥11.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.1bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.5bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥11.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥11.2bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.5bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥68.32 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥176.96 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.77 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.89 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.11 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,004.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,034.03 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,867.4 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,081.9 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,071.6 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 31.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.9% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.7% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,261,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,261,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 347 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 352 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 403 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 450 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 479 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥26m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥62m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 63 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥31m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥96m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥42m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥8.9bn |
| Medicinereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Medicinereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Medicinereportable segment | employees | at 2022-03-31 | 713 pure |
| Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥31.5bn |
| Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥31.5bn |
| Medicinereportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10m |
| Medicinereportable segment | segment assets | at 2022-03-31 | ¥38.6bn |
| Medicinereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥729m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥32.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥32.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥40.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥825m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2020-04-01 → 2021-03-31 | ¥17m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-04-01 → 2021-03-31 | ¥71m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-04-01 → 2021-03-31 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-04-01 → 2021-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥93m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-03-31 | ¥2.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-04-01 → 2021-03-31 | ¥17m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥107m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥107m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥8.2bn |
| Medicinereportable segment | capex | 2020-04-01 → 2021-03-31 | ¥1.8bn |
| Medicinereportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.3bn |
| Medicinereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥30.4bn |
| Medicinereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥30.4bn |
| Medicinereportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥13m |
| Medicinereportable segment | segment assets | at 2021-03-31 | ¥36.4bn |
| Medicinereportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥546m |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥31.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥107m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥38.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥564m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 2 pure |
| Medicinereportable segment | employees | at 2022-03-31 | 312 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,726
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)山口 一城 | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)ゼリア新薬工業株式会社 | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋小舟町10番11号 | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)日本ケミファ従業員持株会 | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目８番12号 | |
| Name major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)245 SUMMER STREET BOSTON,MA 02210 U.S.A.（東京都千代田区丸の内二丁目７番１号） | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)日本ケミファ株式会社 | |
| Address of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Classes of shares etc (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of shareholders meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Disposals or holding of acquired treasury shares (text) | FilingDateInstant | Text · Plus | |
| Dividend policy (text) | FilingDateInstant | Text · Plus | |
| Date of resolution dividends of surplus | FilingDateInstant_Row1Member | 2022-06-24 | |
| Resolution dividends of surplus | FilingDateInstant_Row1Member | Original text (Japanese)定時株主総会決議 | |
| Overview of corporate governance (text) | FilingDateInstant | Text · Plus | |
| Corporate governance company with corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Basic policy regarding control of company (text) | FilingDateInstant | Text · Plus | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamaguchiKazushiroMember | Original text (Japanese)代表取締役社長 代表執行役員社長 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamaguchiKazushiroMember | Original text (Japanese)山 口 一 城 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamaguchiKazushiroMember | 1958-07-23 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00957-000YamaguchiKazushiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamaguchiKazushiroMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000KutsuwadaMasanoriMember | Original text (Japanese)取締役 専務執行役員経営全般補佐 リスク管理・法令等遵守・薬事管理室・総務部・人事部・海外事業部担当 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000KutsuwadaMasanoriMember | Original text (Japanese)轡 田 雅 則 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000KutsuwadaMasanoriMember | 1955-06-03 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00957-000KutsuwadaMasanoriMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000KutsuwadaMasanoriMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamakawaTomioMember | Original text (Japanese)取締役 常務執行役員創薬研究所・開発企画部・製剤技術開発部・海外技術開発部担当 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamakawaTomioMember | Original text (Japanese)山 川 富 雄 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamakawaTomioMember | 1954-06-07 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00957-000YamakawaTomioMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YamakawaTomioMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YasumotoMasahideMember | Original text (Japanese)取締役 執行役員情報システム部・広報室・臨床検査薬事業部担当兼経営企画部長兼ヘルスケア部長 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YasumotoMasahideMember | Original text (Japanese)安 本 昌 秀 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00957-000YasumotoMasahideMember | 1967-10-20 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |